Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 998-1003

  Sherman, Alexander E ^a   Motyckova, Gabriela ^b   Fega, K Rebecca ^c   DeAngelo, Daniel J ^b   Abel, Gregory A ^b   Steensma, David ^b   Wadleigh, Martha ^b   Stone, Richard M ^b   Driver, Jane A ^b,d,e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute; Comorbidity; Geriatric assessment; Leukemia; Myeloid; Performance status; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DAILY LIFE ACTIVITY; DISEASE SPECIFIC SURVIVAL; FEMALE; GERIATRIC ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAIN; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SELF REPORT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ACUTE; COMORBIDITY; GERIATRIC ASSESSMENT; LEUKEMIA; MYELOID; PERFORMANCE STATUS; PROGNOSIS;

AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; GERIATRIC ASSESSMENT; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84880941296     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.05.013     Document Type: Article

References (33)

1. U.S. Interim Projections by Age, Sex, Race and Hispanic Origin, U.S.C., Bureau, Editor; 2004.
2. Howlader N., Noon A.M., Krapcho M., Neyman N., Aminou R., Altekruse S.F., et al. SEER Cancer Statistics Review 2012.
3. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107(9):3481-3485.
4. Wedding U., Rohrig B., Klippstein A., et al. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 2006, 132(10):665-671.
5. Pal S.K., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 2010, 60(2):120-132.
6. Sekeres M.A., Stone R.M., Zahrieh D., et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004, 18(4):809-816.
7. Balducci L., Colloca G., Cesari M., et al. Assessment and treatment of elderly patients with cancer. Surg Oncol 2010, 19(3):117-123.
8. Hurria A., Gupta S., Zauderer M., et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005, 104(9):1998-2005.
9. Klepin H.D., Geiger A.M., Tooze J.A., et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc 2011, 59(10):1837-1846.
10. Behringer B., Pitako J.A., Kunzmann R., et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Ann Hematol 2003, 82(7):381-389.
11. Lengfelder E., Hanfstein B., Haferlach C., et al. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol 2012.
12. Chauncey T.R., Gundacker H., Shadman M., et al. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion: without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol 2010, 148(1):48-58.
13. O'Donnell M.R., Abboud C.N., Altman J., et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2011, 9(3):280-317.
14. Kantarjian H.M., Thomas X.G., Dmoszynska A., et al. Multicenter: randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30(21):2670-2677.
15. Pigneux A., Harousseau J.L., Witz F., et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. J Clin Oncol 2010, 28(18):3028-3034.
16. Spataro V., Kovacsovics T., Bach S., et al. Acute myeloid leukemia in the elderly: results of an individualized approach in two centres. Leuk Lymphoma 2000, 39(5-6):521-530.
17. Djunic I., Virijevic M., Novkovic A., et al. Pretreatment risk factors and importance of comorbidity for overall survival: complete remission, and early death in patients with acute myeloid leukemia. Hematology 2012, 17(2):53-58.
18. Savic A., Kvrgic V., Rajic N., et al. The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res 2012, 36(4):479-482.
19. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106(8):2912-2919.
20. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(3):453-474.
21. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis: standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21(24):4642-4649.
22. Rowe J.M., Kim H.T., Cassileth P.A., et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010, 116(21):5012-5021.
23. Krug U., Rollig C., Koschmieder A., et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010, 376(9757):2000-2008.
24. Wahlin A., Markevarn B., Golovleva I., et al. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001, 115(1):25-33.
25. Juliusson G., Antunovic P., Derolf A., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113(18):4179-4187.
26. Walter R.B., Othus M., Borthakur G., et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011, 29(33):4417-4423.
27. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106(5):1090-1098.
28. Studenski S., Perera S., Patel K., et al. Gait speed and survival in older adults. JAMA 2011, 305(1):50-58.
29. Etienne A., Esterni B., Charbonnier A., et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007, 109(7):1376-1383.
30. Giles F.J., Borthakur G., Ravandi F., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007, 136(4):624-627.
31. Feeny D., Huguet N., McFarland B.H., et al. Hearing, mobility, and pain predict mortality: a longitudinal population-based study. J Clin Epidemiol 2012, 65(7):764-777.
32. Colovic M., Colovic N., Radojkovic M., et al. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients. Ann Hematol 2012.
33. Kantarjian H., Ravandi F., O'Brien S., et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010, 116(22):4422-4429.